Mankind Pharma reported a 39% increase in net profit for the second quarter of the financial year 2026-27, reaching ₹711 crore. This growth was supported by higher revenues and improved operating margins, which attracted positive attention from investors.
- Net profit rose 39% year-on-year to ₹711 crore in Q2 FY27.
- Revenue from core operations increased 17.3% to ₹4,338 crore.
- Operating margins improved by 300 basis points to 30%.
- EBITDA grew 27.2% to ₹1,175 crore with margins expanding 210 basis points.
- Stock price rose 5.4% after the earnings announcement.
What were the key financial results for Mankind Pharma in Q2 FY27?
Mankind Pharma’s consolidated net profit for the July to September quarter of FY27 was ₹711 crore, up 39% from ₹512 crore in the same quarter last year. The company’s revenue from core operations increased by 17.3% to ₹4,338 crore compared to ₹3,697 crore in the previous year’s quarter.
The operating margin improved significantly by 300 basis points, reaching 30% in Q2 FY27, compared to 27% in the same period last year. Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 27.2% to ₹1,175 crore, with EBITDA margins expanding by 210 basis points to 27.1% from 25% a year ago.
How did the stock market respond to Mankind Pharma’s Q2 results?
Following the earnings announcement, Mankind Pharma’s stock price increased by 5.4%, reaching an intraday high of ₹2,333.90 on October 26, 2026. The stock closed at ₹2,312, up from ₹2,212.60 at the previous close. This rise reflected investor confidence in the company’s strong financial performance and margin improvements.
What factors contributed to Mankind Pharma’s revenue growth?
The company’s management attributed the revenue growth to strong performance in both domestic and international markets. Growth in exports and domestic sales helped drive the 17.3% increase in revenue from core operations during the quarter.
What strategic developments did Mankind Pharma announce?
Mankind Pharma highlighted its recent acquisition of Armed Cell Therapeutics, marking a strategic entry into next-generation CAR-T therapies. This move is expected to strengthen the company’s research and development capabilities and support future growth.
How has Mankind Pharma’s stock performed over time?
Year-to-date, Mankind Pharma shares have delivered a 6.8% return to investors. However, the stock declined by 6.5% over the past month but rose 2.6% in the last week. Over the last three years, the stock has gained nearly 36%, though it decreased by 4.9% in the past year. The 52-week high was ₹2,642 on July 29, 2026, and the low was ₹1,909.70 on March 23, 2026.
As of October 26, 2026, the company’s market capitalization stood at ₹95,496 crore.
Frequently Asked Questions
Q: What was Mankind Pharma’s net profit in Q2 FY27?
A: The net profit was ₹711 crore, a 39% increase compared to the previous year.
Q: How much did the operating margin improve?
A: Operating margins improved by 300 basis points to 30% in Q2 FY27.
Q: What recent acquisition did Mankind Pharma make?
A: The company acquired Armed Cell Therapeutics, entering the next-generation CAR-T therapy market.
